Grifols A : China Resources weighing deal for Grifols’ stake in Shanghai RAAS
>China Resources is considering buying part of Grifols’ stake in Shanghai RAAS - After Grifols announced (June 13) to the market their intention to partially dispose of the stake in Shanghai Raas we now know that China Resources Holdings is the potential buyer. The companies are in talks about a potential transaction that would help Grifols cut its debt. Additionally, other healthcare groups and investment firms have also expressed interest in acquiring the stake. If ...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.